Household Products

C&S released FY2026 Q1 earnings on April 27 After-Market (BJT), actual revenue CNY 2.198 B, actual EPS CNY 0.08

C&S to Release FY2026 Q1 Earnings on April 28 After-Market (BJT)

C&S released FY2025 Q4 earnings on April 14 After-Market (BJT), actual revenue CNY 2.302 B, actual EPS CNY 0.0701 (forecast EPS CNY 0.07)

C&S released FY2025 Annual Earnings on April 14 After-Market (BJT), Actual Revenue CNY 8.78 B (Forecast CNY 9.056 B), Actual EPS CNY 0.25 (Forecast CNY 0.2433)

C&S to release FY2025 earnings on April 15 After-Market (BJT), forecast revenue CNY 9.056 B, EPS CNY 0.2433

C&S released FY2025 Q3 earnings on October 27 After-Market (BJT), actual revenue CNY 2.149 B, actual EPS CNY 0.0599

C&S released FY2025 9 Months Earnings on October 27 After-Market (BJT), actual revenue CNY 6.478 B, actual EPS CNY 0.1814

C&S to Release FY2025 Q3 Earnings on October 28 After-Market (BJT)

C&S released FY2025 Q2 earnings on August 19 After-Market (BJT), actual revenue CNY 2.262 B, actual EPS CNY 0.0714

C&S released FY2025 Semi-Annual Earnings on August 19 After-Market (BJT), actual revenue CNY 4.33 B, actual EPS CNY 0.12

C&S FY2025 Semi-Annual Earning Release on August 20, 2025 (BJT)

Zhongshun Jieruo Establishes Apparel Company

Zhongshun Jierong Predicts 59.85%-82.68% Net Profit Growth in H1 2025

Zhongshun Jierong Submits New Trademark Applications

RMB appreciation lowers Zhongshun Jierong's procurement costs

Zhongshun Jierong Adjusts Share Repurchase Amount

Huansan Securities Releases Research Report on Zhongshun Jierou

Zhongshun Jierong Releases Q1 2025 Earnings Report

C&S released FY2024 annual earnings on April 24 After-Market (BJT), actual revenue CNY 8.151 B (forecast CNY 9.15 B), actual EPS CNY 0.06 (forecast CNY 0.26)

C&S released FY2024 Q4 earnings on April 24 After-Market (BJT), actual revenue CNY 2.195 B (forecast CNY 3.199 B), actual EPS CNY 0.0209

002511

300174

159787

On the first trading day of the Year of the Horse, several listed companies announced their repurchase and increase plans and progress, including the repurchase plans of C&S and YUANLI ACTIVE CARBON, as well as the increase plans of CONCH CEMENT and HHP. Companies such as JIUDIAN PHARMACEUTICAL and Ningbo Sunrise also updated their repurchase progress

Wallstreetcn

YUANLI ACTIVE CARBON

E Fund CSI All Share Building Materials ETF

CONCH CEMENT

Fullgoal CSI 1000 Enhanced Index Fund(LOF)-A

Ningbo Sunrise

JIUDIAN PHARMACEUTICAL

Fullgoal CSI All Share Building Materials ETF

Guotai CSI All Share building Materials ETF

On the first trading day of the Year of the Horse, the trend of share repurchases and increases in holdings by A-share listed companies continues

C&S: Due to personal career development plans, Mr. Liu Peng has applied to resign from his positions as a director, chairman, member of the nomination committee, member of the strategy and sustainable development committee, and legal representative of the company. After his resignation, he will still hold other positions within the company

According to the Zhitong Finance APP, C&S announced that as of October 31, 2025, the company has repurchased a total of 24.2447 million shares through centralized bidding, accounting for approximately 1.88% of the company's current total share capital, with a total transaction amount of 184 million yuan (excluding transaction fees)

Zhitong

C&S has repurchased 1.88% of its shares at a cost of 184 million yuan

688363

According to Tianyancha's business information, recently, Beijing Bloomage Biotech Co., Ltd. changed its registration status from active to canceled. Previously, the company had issued a simple cancellation announcement. The company was established in September 2021, with Zhao Ming as the legal representative, a registered capital of 10 million RMB, and its business scope includes the sale of paper products, daily necessities, sanitary products, cosmetics, etc., with C&S and Bloomage Biotech holding 51% and 49% of the shares, respectively

Bloomage Biotech

C&S and Bloomage Biotech's joint venture biotechnology company has been deregistered

According to the Zhitong Finance APP, C&S announced that as of August 31, 2025, the company has repurchased a total of 21.3222 million shares through a dedicated securities account via centralized bidding, accounting for 1.66% of the company's current total share capital, with a total transaction amount of 160 million yuan (excluding transaction fees)

C&S has repurchased 1.66% of its shares at a cost of 160 million yuan

C&S released its 2025 semi-annual report, with operating revenue of 4.33 billion yuan, a year-on-year increase of 7.67%; net profit attributable to shareholders of the parent company was 150 million yuan, a year-on-year increase of 71.44%; net profit excluding non-recurring gains and losses was 147 million yuan, a year-on-year increase of 113.26%. Basic earnings per share were 0.12 yuan, and it proposed to distribute a cash dividend of 0.63 yuan (including tax) for every 10 shares to all shareholders

C&S released its performance for the first half of the year, with a net profit attributable to shareholders of 150 million yuan, an increase of 71.44%

C&S announced that a board meeting will be held on August 18, 2025, to review and approve the adjustment of the share repurchase plan. The adjustment includes: the total repurchase amount will be adjusted from no less than 11 million yuan to no less than 16 million yuan, and the source of funds will be adjusted from self-owned funds to self-owned funds and self-raised funds

C&S: Adjusting the share repurchase plan with a total funding amount of no less than 160 million yuan

According to the Qichacha APP, recently, Shanghai Xijing Ningshi Biotechnology Co., Ltd. was established, with Liang Geyu as the legal representative and a registered capital of 1 million yuan. The business scope includes: wholesale of cosmetics; retail of cosmetics; sales of personal hygiene products; sales of Class I medical devices; corporate image planning, etc. Qichacha's equity penetration shows that the company is jointly held by Jiangmen Zhongshun Paper Co., Ltd., a subsidiary of C&S, and Shi Chunli

C&S and others established a biotechnology company

C&S expects its net profit attributable to the parent company in the first half of 2025 to be between 140 million and 160 million yuan, a year-on-year increase of 59.85%-82.68%. The net profit after deducting non-recurring gains and losses is expected to be between 135 million and 155 million yuan, a year-on-year increase of 95.95%-124.98%. The company has improved its operating income and profitability by optimizing its business structure and cost control

C&S announced a preliminary increase, expecting a net profit attributable to the parent company of 140 million to 160 million yuan in the first half of the year, a year-on-year increase of 59.85%-82.68%

C&S plans to launch the fourth employee stock ownership plan, with no more than 150 participants, including 6 directors and senior management. The plan aims to raise no more than 77.74 million yuan, with a subscription unit of 1.00 yuan and a maximum of 77.74 million shares. After approval by the shareholders' meeting, the plan will legally purchase no more than 23 million repurchased shares at a price of 3.38 yuan per share, accounting for 1.78% of the company's total equity

C&S plans to launch the fourth employee stock ownership plan

C&S(002511.SZ)